AGDA KARINA B. ETEROVIC to Antineoplastic Agents
This is a "connection" page, showing publications AGDA KARINA B. ETEROVIC has written about Antineoplastic Agents.
Connection Strength
0.143
-
Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. J Invest Dermatol. 2019 03; 139(3):728-731.
Score: 0.032
-
Drug-resistance in central nervous system tumors: from the traditional cell-resistance model to the genetically driven approaches on therapy. Curr Pharm Biotechnol. 2007 Apr; 8(2):105-13.
Score: 0.029
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.025
-
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57.
Score: 0.024
-
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010 Mar; 12(3):233-42.
Score: 0.018
-
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017 02 02; 129(5):572-581.
Score: 0.007
-
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell. 2015 Oct 12; 28(4):515-528.
Score: 0.007